文献速递妇科产科

预防性低位腹主动脉旁照射采用调强放疗降低局部晚期宫颈癌腹主动脉旁复发风险:一家机构10年经验

Prophylactic lower para-aortic irradiation using intensity-modulated radiotherapy mitigates the risk of para-aortic recurrence in locally advanced cervical cancer: A 10-year institutional experience.
PubMed 文献 · Gynecol Oncol · 2017-04-27

本机构2004至2013年回顾性分析了206例FIGO IB2-IVA期、腹主动脉旁淋巴结阴性的宫颈癌患者,分别接受盆腔调强放疗(PRT)或预防性肾静脉下放疗(SRVRT)。SRVRT组5年腹主动脉旁淋巴结无复发生存率和总生存率均优于PRT组,且未显著增加严重晚期毒性。

要点

  • SRVRT较PRT改善5年腹主动脉旁淋巴结无复发生存率(97.9% vs 87.6%,p=0.03)和总生存率(87.8% vs 74.5%,p=0.04)。
  • 在FIGO III-IVA期或盆腔淋巴结阳性患者中,SRVRT的5年PARFS和OS获益更明显。
  • 多因素分析仅SRVRT与更好的PARFS相关(HR 0.21,95%CI 0.06-0.78,p=0.02)。

核心结论

  • 预防性SRVRT使用IMRT减少了腹主动脉旁淋巴结复发,毒性可耐受,支持基于风险的宫颈癌放疗野应用。

研究设计与样本

  • 回顾性综述了2004年至2013年在本机构接受盆腔IMRT(PRT)或SRVRT的206例FIGO IB2-IVA期宫颈癌且腹主动脉旁淋巴结阴性患者。
  • SRVRT将PRT野的头侧扩展至左肾静脉水平以覆盖腹主动脉旁淋巴结,处方剂量统一为50.4Gy分28次。

主要发现

  • 全研究人群PRT组与SRVRT组的5年PARFS分别为87.6%与97.9%(p=0.03),5年OS分别为74.5%与87.8%(p=0.04)。
  • FIGO III-IVA期或盆腔淋巴结阳性患者中,PRT组与SRVRT组的5年PARFS分别为80.1%与96.4%(p=0.02),5年OS分别为58.1%与83.5%(p=0.012)。
  • FIGO IB-IIB期且盆腔淋巴结阴性患者中,上述结局无显著差异。
  • 多因素分析中仅SRVRT与更好的PARFS相关(HR 0.21,95%CI 0.06-0.78,p=0.02)。
  • SRVRT未显著增加严重晚期毒性。

临床怎么用

  • 原文结论支持基于风险的放疗野选择,SRVRT可减少腹主动脉旁淋巴结复发且毒性可耐受。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effects of prophylactic sub-renal vein radiotherapy (SRVRT) using intensity-modulated radiotherapy (IMRT) for cervical cancer. METHODS: A total of 206 patients with FIGO stage IB2-IVA cervical cancer and negative para-aortic lymph nodes (PALNs) who underwent pelvic IMRT (PRT) or SRVRT between 2004 and 2013 at our institution were reviewed. SRVRT cranially extended the PRT field for PALNs up to the left renal vein level. The prescribed dose was consistent 50.4Gy in 28 fractions. RESULTS: Overall, 110 and 96 patients underwent PRT and SRVRT, respectively. The SRVRT group had more advanced disease based on FIGO stage and positive pelvic lymph nodes (PLNs). The median follow-up time was 60months (range, 7-143). For the total study population, the 5-year PALN recurrence-free survival (PARFS) and overall survival (OS) for PRT vs. SRVRT were 87.6% vs. 97.9% (p=0.03) and 74.5% vs. 87.8% (p=0.04), respectively. In patients with FIGO III-IVA or positive PLNs, the 5-year PARFS and OS for PRT vs. SRVRT were 80.1% vs. 96.4% (p=0.02) and 58.1% vs. 83.5% (p=0.012), respectively. However, there were no significant differences in these outcomes for patients with FIGO IB-IIB and negative PLNs. In a multivariate analysis, only SRVRT was associated with better PARFS (HR, 0.21; 95% CI, 0.06-0.78; p=0.02). The SRVRT did not significantly increase severe late toxicities. CONCLUSION: Prophylactic SRVRT using IMRT reduced PALN recurrence with tolerable toxicities, supporting the application of risk-based radiation fields for cervical cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lee J, Lin JB, Chang CL, et al. Prophylactic lower para-aortic irradiation using intensity-modulated radiotherapy mitigates the risk of para-aortic recurrence in locally advanced cervical cancer: A 10-year institutional experience. Gynecol Oncol. 2017. PMID: 28457584. doi:10.1016/j.ygyno.2017.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。